A biotechnology company with clinical-stage assets positioned in several neuropsychiatric disorders wanted to supplement its internal pipeline with external innovation. The company wanted to add small molecule assets that elicit psychedelic episodes and do so via specific activation of an identified biological signaling pathway. These assets could range in development stage from 6-9 months pre-IND through Phase 1 development and had to be targeting certain neuropsychiatric indications of interest. The company engaged Alacrita to identify potential partners and assets for in-licensing, with a particular focus in the US and Europe.


Alacrita conducted a comprehensive search of development assets that matched the target company's therapeutic focus and clinical development stage criteria. We generated an initial long list of opportunities and through a series of assessments and iterative discussions with our client, we filtered the database to yield a list of ~100 potential opportunities that represented the best combination of fit and potential availability. From this list, we conducted outreach to confirm asset availability and degeree of fit. The client's internal BD team then initiated discussions with the sponsor's of the most interesting assets identified.


Alacrita's Asset Scouting & In-Licensing Services

Alacrita supports both large pharma and biotech companies with their search and evaluation activities. Our scouting support is often structured to integrate with the client’s internal efforts, resulting in a constant flow of new opportunities.

Click here to learn more